A Phase III, Prospective, Randomized, Open-Labeled, Active-Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine, GC FLU, in Adults Aged 20 to 50
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs GC 3110A (Primary) ; GSK 2321138A
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Medigen Vaccine Biologics
- 12 Aug 2019 Status changed from active, no longer recruiting to completed.
- 20 Feb 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 01 Nov 2018 New trial record